Jianyuan Luo
Directeur/Membre du Conseil chez Continent Pharmaceutical Inc.
Profil
Jian Yuan Luo is an Independent Non-Executive Director at Continent Pharmaceutical Inc. and Beijing Continent Pharmaceutical Co., Ltd.
He is also a Council Member-Beijing Orphan Disease Brach at The Chinese Medical Association.
Previously, he worked as an Associate Professor at the University of Maryland from 2010 to 2015.
He received his undergraduate and graduate degrees from Peking University and his doctorate from the University of Kentucky.
Postes actifs de Jianyuan Luo
| Sociétés | Poste | Début |
|---|---|---|
Continent Pharmaceutical Inc.
 Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | Directeur/Membre du Conseil | 01/01/2019 |
| The Chinese Medical Association | Corporate Officer/Principal | 01/02/2013 |
Beijing Continent Pharmaceutical Co., Ltd.
 Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Directeur/Membre du Conseil | - |
Anciens postes connus de Jianyuan Luo
| Sociétés | Poste | Fin |
|---|---|---|
| University of Maryland | Corporate Officer/Principal | 01/01/2015 |
Formation de Jianyuan Luo
| Peking University | Undergraduate Degree |
| University of Kentucky | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Continent Pharmaceutical Inc.
Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | Health Technology |
| The Chinese Medical Association | |
Beijing Continent Pharmaceutical Co., Ltd.
Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Health Technology |